Journal Article DZNE-2025-00325

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2025
Springer Nature [New York, NY]

Nature medicine 31(2), 478 - 489 () [10.1038/s41591-024-03420-w]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: Genetic diagnosis of rare diseases requires accurate identification and interpretation of genomic variants. Clinical and molecular scientists from 37 expert centers across Europe created the Solve-Rare Diseases Consortium (Solve-RD) resource, encompassing clinical, pedigree and genomic rare-disease data (94.5% exomes, 5.5% genomes), and performed systematic reanalysis for 6,447 individuals (3,592 male, 2,855 female) with previously undiagnosed rare diseases from 6,004 families. We established a collaborative, two-level expert review infrastructure that allowed a genetic diagnosis in 506 (8.4%) families. Of 552 disease-causing variants identified, 464 (84.1%) were single-nucleotide variants or short insertions/deletions. These variants were either located in recently published novel disease genes (n = 67), recently reclassified in ClinVar (n = 187) or reclassified by consensus expert decision within Solve-RD (n = 210). Bespoke bioinformatics analyses identified the remaining 15.9% of causative variants (n = 88). Ad hoc expert review, parallel to the systematic reanalysis, diagnosed 249 (4.1%) additional families for an overall diagnostic yield of 12.6%. The infrastructure and collaborative networks set up by Solve-RD can serve as a blueprint for future further scalable international efforts. The resource is open to the global rare-disease community, allowing phenotype, variant and gene queries, as well as genome-wide discoveries.

Keyword(s): Humans (MeSH) ; Rare Diseases: genetics (MeSH) ; Rare Diseases: diagnosis (MeSH) ; Europe (MeSH) ; Male (MeSH) ; Genomics: methods (MeSH) ; Female (MeSH) ; Pedigree (MeSH) ; Databases, Genetic (MeSH) ; Computational Biology: methods (MeSH) ; Genome, Human: genetics (MeSH) ; Exome: genetics (MeSH)

Classification:

Contributing Institute(s):
  1. Parkinson Genetics (AG Gasser)
  2. Clinical Neurogenetics (AG Schöls)
Research Program(s):
  1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2025
Database coverage:
Medline ; Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 ; OpenAccess ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Nature ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 80 ; JCR ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > TÜ DZNE > TÜ DZNE-AG Schöls
Institute Collections > TÜ DZNE > TÜ DZNE-AG Gasser
Full Text Collection
Public records
Publications Database


Linked articles:

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article (Erratum/Correction)  ;  ;  ; et al
Publisher Correction: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses.
Nature medicine 31(8), 2819 - 2820 () [10.1038/s41591-025-03754-z] OpenAccess  Download fulltext Files  Download fulltextFulltext by Pubmed Central BibTeX | EndNote: XML, Text | RIS


 Record created 2025-02-20, last modified 2025-03-23


OpenAccess:
Download fulltext PDF Download fulltext PDF (PDFA)
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)